MX2013000219A - Preparacion de tesetaxel y compuestos relacionados e intermediario de sintesis correspondiente. - Google Patents

Preparacion de tesetaxel y compuestos relacionados e intermediario de sintesis correspondiente.

Info

Publication number
MX2013000219A
MX2013000219A MX2013000219A MX2013000219A MX2013000219A MX 2013000219 A MX2013000219 A MX 2013000219A MX 2013000219 A MX2013000219 A MX 2013000219A MX 2013000219 A MX2013000219 A MX 2013000219A MX 2013000219 A MX2013000219 A MX 2013000219A
Authority
MX
Mexico
Prior art keywords
preparation
tesetaxel
related compounds
synthesis intermediate
corresponding synthesis
Prior art date
Application number
MX2013000219A
Other languages
English (en)
Inventor
John K Thottathil
Raymond P Warrell Jr
Original Assignee
Genta Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genta Inc filed Critical Genta Inc
Publication of MX2013000219A publication Critical patent/MX2013000219A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención proporciona un método para la preparación de compuestos de taxano pentacíclicos oralmente disponibles, así como intermediarios (la) utiles en su preparación.
MX2013000219A 2010-06-30 2011-06-29 Preparacion de tesetaxel y compuestos relacionados e intermediario de sintesis correspondiente. MX2013000219A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36013510P 2010-06-30 2010-06-30
US13/170,830 US8785669B2 (en) 2010-06-30 2011-06-28 Taxane compounds, compositions and methods
PCT/US2011/042299 WO2012003199A1 (en) 2010-06-30 2011-06-29 Preparation of tesetaxel and related compounds and corresponding synthesis intermediate

Publications (1)

Publication Number Publication Date
MX2013000219A true MX2013000219A (es) 2013-05-20

Family

ID=45400196

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013000219A MX2013000219A (es) 2010-06-30 2011-06-29 Preparacion de tesetaxel y compuestos relacionados e intermediario de sintesis correspondiente.

Country Status (13)

Country Link
US (2) US8785669B2 (es)
EP (1) EP2588482B1 (es)
JP (1) JP5960130B2 (es)
KR (1) KR20130114074A (es)
CN (1) CN103025739A (es)
AU (1) AU2011271489A1 (es)
CA (1) CA2804031A1 (es)
EA (1) EA201291486A1 (es)
ES (1) ES2706699T3 (es)
MX (1) MX2013000219A (es)
SG (1) SG186823A1 (es)
TW (1) TW201206895A (es)
WO (1) WO2012003199A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8785669B2 (en) * 2010-06-30 2014-07-22 Gfv, Llc Taxane compounds, compositions and methods
WO2013162922A1 (en) * 2012-04-25 2013-10-31 Genta Incorporated Taxane compounds, compositions and methods
AU2015237200A1 (en) 2014-03-27 2016-10-06 The Brigham And Women's Hospital, Inc. Metabolically-activated drug conjugates to overcome resistance in cancer therapy

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY110249A (en) 1989-05-31 1998-03-31 Univ Florida State Method for preparation of taxol using beta lactam
US6794523B2 (en) 1991-09-23 2004-09-21 Florida State University Taxanes having t-butoxycarbonyl substituted side-chains and pharmaceutical compositions containing them
US5710287A (en) * 1991-09-23 1998-01-20 Florida State University Taxanes having an amino substituted side-chain and pharmaceutical compositions containing them
IL108316A (en) * 1993-01-15 2006-10-31 Univ Florida State History of C-10 Texan and pharmaceuticals containing them
TW467896B (en) 1993-03-19 2001-12-11 Bristol Myers Squibb Co Novel β-lactams, methods for the preparation of taxanes and sidechain-bearing taxanes
ES2164241T3 (es) 1995-04-28 2002-02-16 Daiichi Seiyaku Co Compuestos pentaciclicos.
US5695944A (en) 1995-05-05 1997-12-09 Thomas Jefferson University Modulation of bcl-2 phosphorylation
JP2000159757A (ja) 1998-12-01 2000-06-13 Dai Ichi Seiyaku Co Ltd ７−デオキシタキソール誘導体の製造方法
US6677456B2 (en) 1999-10-15 2004-01-13 Daiichi Pharmaceutical Co., Ltd. Pentacyclic taxan compound
MXPA02003797A (es) * 1999-10-15 2002-12-13 Daiichi Seiyaku Co Compuestos de taxano pentaciclico.
JP4142444B2 (ja) 2001-03-07 2008-09-03 第一三共株式会社 ２−アゼチジノン誘導体の製造方法
EP1457492B1 (en) 2001-11-29 2008-01-02 Daiichi Sankyo Company, Limited Crystals of taxane derivative and process for their production
DK1741716T3 (da) 2004-04-30 2011-11-28 Daiichi Sankyo Co Ltd Fremgangsmåde til fremstilling af pentacyklisk taxan
US20090186868A1 (en) 2005-10-25 2009-07-23 Daiichi Sankyo Company Limited Taxane Compound Having Azetidine Ring Structure
US8785669B2 (en) * 2010-06-30 2014-07-22 Gfv, Llc Taxane compounds, compositions and methods
WO2013162922A1 (en) * 2012-04-25 2013-10-31 Genta Incorporated Taxane compounds, compositions and methods

Also Published As

Publication number Publication date
SG186823A1 (en) 2013-02-28
CN103025739A (zh) 2013-04-03
CA2804031A1 (en) 2012-01-05
EP2588482B1 (en) 2018-10-24
EP2588482A1 (en) 2013-05-08
AU2011271489A1 (en) 2013-01-17
ES2706699T3 (es) 2019-03-29
WO2012003199A1 (en) 2012-01-05
EA201291486A1 (ru) 2013-05-30
US9434740B2 (en) 2016-09-06
US8785669B2 (en) 2014-07-22
JP2013530234A (ja) 2013-07-25
KR20130114074A (ko) 2013-10-16
US20120004429A1 (en) 2012-01-05
JP5960130B2 (ja) 2016-08-02
TW201206895A (en) 2012-02-16
US20150080578A1 (en) 2015-03-19

Similar Documents

Publication Publication Date Title
MX336682B (es) Anticuerpos contra csf-1r humanos y usos de los mismos.
TW201129381A (en) Antibodies against human CSF-1R and uses thereof
AU2010233994A8 (en) Bispecific anti-ErbB-3/anti-c-Met antibodies
MX340558B (es) Anticuerpos biespecificos que comprenden fragmento fv estabilizado con disulfuro.
MA34091B1 (fr) Anticorps anti-cd40
PH12014502010A1 (en) Bispecific antibodies against human tweak and human il17 and uses thereof
TN2011000673A1 (en) Bace inhibitors
MY163339A (en) A method of producing ingenol-3-angelate
MX2010003599A (es) Intermediarios y metodos para la sintesis de analogos de halicondrina b.
MX2012007340A (es) Anticuerpos anti/her3 y usos de los mismos.
IN2014CN04160A (es)
UA103794C2 (en) Liposome composition
SG178886A1 (en) Humanized anti-cdcp1 antibodies
GEP20135903B (en) Method of (1s, 2r)-milnacipran synthesis
MX2011010012A (es) NUEVOS ANTICUERPOS ANTI-A5ß1 Y SUS USOS.
MX2014002996A (es) Anticuerpos anti - egfr/anti - igf-1r bisespecificos.
MX360872B (es) Nuevas composiciones para la produccion de poliamidas coladas.
MX2015007778A (es) Prediccion de bioactivacion molecular.
TN2013000354A1 (en) Synthesis of 2-carboxamide cycloamino urea derivatives
GEP201706626B (en) Synthesis of (s)-nifuratel
EA201200820A1 (ru) Способ синтеза промежуточных продуктов, применимых для получения замещенных индазолов и азаиндазолов
EP2576575A4 (en) PROSTAGLANDIN-BISPHOSPHONATE CONJUGATE COMPOUNDS, THEIR METHODS OF MANUFACTURE AND USES THEREOF
CL2012003371A1 (es) Compuestos intermediarios de la síntesis de agomelatina; y el procedimiento de obtención de agomelatina a partir de dichos compuestos intermediarios
MX2012010443A (es) Proceso para la preparacion de 1-alquiltetrazoles 5-sustituidos.
MX2013000219A (es) Preparacion de tesetaxel y compuestos relacionados e intermediario de sintesis correspondiente.

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: GFV, LLC

HC Change of company name or juridical status

Owner name: GFV, LLC

FA Abandonment or withdrawal